Phibro Animal Health (NASDAQ:PAHC) Cut to “Buy” at StockNews.com

Phibro Animal Health (NASDAQ:PAHC) was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Friday.

A number of other brokerages have also issued reports on PAHC. JPMorgan Chase & Co. assumed coverage on shares of Phibro Animal Health in a research report on Tuesday, September 10th. They set a “neutral” rating and a $22.00 target price on the stock. Barclays raised their price objective on shares of Phibro Animal Health from $13.00 to $20.00 and gave the stock an “underweight” rating in a research report on Tuesday, November 12th. Morgan Stanley upped their target price on shares of Phibro Animal Health from $20.00 to $25.00 and gave the company an “equal weight” rating in a report on Tuesday, December 17th. Finally, Bank of America raised their price target on Phibro Animal Health from $13.00 to $15.00 and gave the stock an “underperform” rating in a report on Friday, August 30th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $20.50.

Phibro Animal Health Stock Performance

Shares of Phibro Animal Health stock traded down $0.63 on Friday, hitting $21.05. The stock had a trading volume of 188,651 shares, compared to its average volume of 160,571. The company’s 50 day moving average price is $23.35 and its 200 day moving average price is $20.81. The stock has a market cap of $852.59 million, a price-to-earnings ratio of 48.95, a P/E/G ratio of 0.58 and a beta of 0.51. The company has a current ratio of 3.23, a quick ratio of 1.69 and a debt-to-equity ratio of 1.81. Phibro Animal Health has a 52-week low of $10.03 and a 52-week high of $25.98.

Institutional Investors Weigh In On Phibro Animal Health

A number of institutional investors have recently added to or reduced their stakes in PAHC. BNP Paribas Financial Markets lifted its holdings in Phibro Animal Health by 3.1% in the third quarter. BNP Paribas Financial Markets now owns 24,336 shares of the company’s stock valued at $548,000 after acquiring an additional 729 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in shares of Phibro Animal Health by 63.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 3,912 shares of the company’s stock valued at $88,000 after purchasing an additional 1,522 shares during the period. Public Sector Pension Investment Board boosted its holdings in Phibro Animal Health by 6.1% during the second quarter. Public Sector Pension Investment Board now owns 44,796 shares of the company’s stock worth $751,000 after buying an additional 2,583 shares in the last quarter. Segall Bryant & Hamill LLC boosted its holdings in Phibro Animal Health by 1.7% during the third quarter. Segall Bryant & Hamill LLC now owns 174,569 shares of the company’s stock worth $3,931,000 after buying an additional 2,971 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new position in Phibro Animal Health during the third quarter worth about $70,000. Hedge funds and other institutional investors own 99.34% of the company’s stock.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.